Skip to content

Scientific Consulting Services

Expert support and insights to fuel research, development, and commercialization.

Get started

Expertise that accelerates evidence generation

Whether preparing for a clinical submission, evaluating real‑world outcomes, or developing market access evidence, our expert team provides the clarity, rigor, and confidence you need to succeed. 

Core capabilities include:
  • Epidemiology and biostatistics 
  • Therapeutic area expertise and study design 
  • Writing protocols and statistical analysis plans, designing and building eCRFs  
  • HEOR, HTA, and market access support 
  • Advanced modeling and analytics services 
  • Regulatory reports, publications, and compliance reviews

Make confident decisions backed by robust, defensible evidence

End‑to‑end evidence delivery

Accelerate your path from feasibility to submission using evidence spanning study design, analysis, and regulatory preparation.

Deep scientific knowledge

Strengthen your evidence base by tapping into our deep expertise in epidemiology, biostatistics, key therapeutic areas, and HEOR / HTA.

Full study package delivery

Reduce operational burden through comprehensive service packages, including study protocols, statistical analysis plans, eCRF design, data management, reports, and more.

Advanced analytics

Improve decision making with analytics and standardized datasets (CDISC, OMOP or custom models, supported by compliance review), anonymized imaging solutions, and exploratory data modeling.

Expertise that delivers results 

Our highly experienced team applies decades of hands‑on scientific, clinical, and technical expertise to keep your projects moving faster and with less risk — delivering consistently high‑quality results. 

20 years of experience per consultant, on average 
70% with PhD and / or master’s degrees 
95% have worked at a life sciences company 
45% with experience in healthcare or public health 
1,000’s of clinical trials supported across diverse therapy areas
150+ technology deployments supported

One partner, limitless opportunities

Enjoy secure collaboration

Work with pharma and policy experts who operate within secure analytics platforms and trusted research environments to get robust deliverables that are ready to use.

Go beyond analysis 

Receive regulatory‑rgrade evidence that supports confident decisions across RWE, market access, and development — not just insights on slides.

Move ahead confidently

Partner with domain scientists you’ll know by name using proven frameworks to move faster, reduce risk and complexity, and turn complex data into action. 

Meet some of our team members

  • Sara K S Bengtsson, PhD

    Sara K S Bengtsson, PhD

    Senior Statistical Programmer
    View Bio
  • Khedidja Hedna Hadj-Kali, PhD

    Khedidja Hedna Hadj-Kali, PhD

    Senior Pharmacoepidemiologist
    View Bio
  • Anders Nordlund, PhD

    Anders Nordlund, PhD

    Senior Statistician
    View Bio


Recent projects

Oncology study: Feasibility to submission

Supported feasibility assessments through submission by harmonizing multi‑modal data, developing study protocols and SAPs, and performing analytics for regulatory milestones.

Market access evidence at scale

Delivered advanced biostatistics and programming to produce benefit dossiers for regulatory submissions.

Rare disease studies for regulatory use

Provided subject‑matter expertise to shape study design, guide data collection, and validate results.

Multi-modal datasets

Ingested, harmonized, and integrated multi‑modal datasets to power research projects and accelerate drug pipelines.

Check out our latest thinking

  • 8 min read

    What Comes Next for Clinical Trials? Mukhtar Ahmed Says “Personalized Research”

    Mukhtar Ahmed discusses how AI, real-world data, and federated analytics could accelerate the shift to personalized research.

    Read more
  • 1 min read

    BC Platforms named Advanced drug development technology of the year in Europe 2026

    BC Platforms has been recognized by Pharma Tech Outlook Europe for leadership in evidence generation and AI-enabled drug development.

    Read more
  • 2 min read

    AI in drug development is not a data problem – it’s an evidence problem

    A new opinion piece by Narasimha Kumar, published in MedCity News, explores why “AI in Drug Development Is Not a Data Problem, It’s an Evidence Problem.” The article examines how the challenge is no longer collecting data, but preserving the context, meaning, and relationships that transform data into usable evidence. Kumar argues that AI cannot

    Read more

Let’s connect to discuss your needs

Contact us to learn more about our solutions or discuss how we can support your needs.  

Let’s connect